Annovis Bio to Participate in A.G.P.'s Virtual Healthcare Symposium
November 16, 2020 09:15 ET
|
Annovis Bio Inc.
BERWYN, Pa., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio Reports Positive Results from Final Phase of $1.9M NIH Funded Chronic Toxicology Study for its Lead Compound for the Treatment of Alzheimer’s and Parkinson’s Diseases
November 12, 2020 06:45 ET
|
Annovis Bio Inc.
BERWYN, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio CEO to Present at Meridian Clinical Trials Summit
November 02, 2020 06:45 ET
|
Annovis Bio Inc.
BERWYN, Pa., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio Resumes Treatment of Patients in Ongoing Phase 2a Study in Alzheimer’s Disease after COVID-Related Delay
October 29, 2020 06:45 ET
|
Annovis Bio Inc.
BERWYN, Pa., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio CEO Receives 2020 Smart Business Dealmaker Award
October 22, 2020 06:45 ET
|
Annovis Bio Inc.
BERWYN, Pa., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio CEO Participates in Roundtable Discussion at the Financial Times’ Outstanding Directors Exchange and Panel Discussion at the Angel Venture Fair
October 20, 2020 06:45 ET
|
Annovis Bio Inc.
BERWYN, Pa., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio Provides Third Quarter 2020 and Year-to-Date Business Highlights
October 15, 2020 06:45 ET
|
Annovis Bio Inc.
BERWYN, Pa., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio to Present at the 2020 BIO Investor Forum
October 12, 2020 16:05 ET
|
Annovis Bio Inc.
BERWYN, Pa., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio Demonstrates Improved Axonal Transport in Nerve Cells and Brain of Down Syndrome Mice, an Animal Model of Alzheimer’s Disease
September 29, 2020 06:45 ET
|
Annovis Bio Inc.
Manuscript Published in Alzheimer's & Dementia: The Journal of the Alzheimer’s Association Study adds further validation that Annovis’ lead compound is the only drug to improve axonal...
Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report
September 03, 2020 06:45 ET
|
Annovis Bio Inc.
BERWYN, Pa., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...